We're raising our price target on Eli Lilly as the obesity-drug boom rolls on

The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.